Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
J Comp Eff Res
; 9(8): 553-562, 2020 06.
Article
em En
| MEDLINE
| ID: mdl-32419473
ABSTRACT
Aim:
To investigate the cost-effectiveness of lenvatinib and sorafenib in the treatment of patients with nonresected hepatocellular carcinoma in China. Materials &methods:
Markov model was used to simulate the direct medical cost and quality-adjusted life years (QALY) of patients with hepatocellular carcinoma. Clinical data were derived from the Phase 3 randomized clinical trial in a Chinese population.Results:
Sorafenib treatment resulted in 1.794 QALYs at a cost of $43,780.73. Lenvatinib treatment resulted in 2.916 QALYs for patients weighing <60 and ≥60 kg at a cost of $57,049.43 and $75,900.36, The incremental cost-effectiveness ratio to the sorafenib treatment group was $11,825.94/QALY and $28,627.12/QALY, respectively.Conclusion:
According to WHO's triple GDP per capita, the use of lenvatinib by providing drugs is a cost-effective strategy.Palavras-chave
Texto completo:
1
Temas:
ECOS
/
Aspectos_gerais
/
Financiamentos_gastos
Bases de dados:
MEDLINE
Assunto principal:
Compostos de Fenilureia
/
Quinolinas
/
Custos de Cuidados de Saúde
/
Análise Custo-Benefício
/
Carcinoma Hepatocelular
/
Sorafenibe
/
Neoplasias Hepáticas
Limite:
Female
/
Humans
/
Male
País/Região como assunto:
Asia
Idioma:
En
Revista:
J Comp Eff Res
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
China